The startup leverages a proprietary technology platform to utilize exosomes for targeted drug delivery, enhancing the efficacy of treatments for various diseases. This method addresses the limitations of traditional therapeutic approaches by improving intercellular communication and precision in drug administration.
Funding
$1.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The increasing global lifespan has led to a rise in age-related disorders and degenerative diseases, creating a disparity between lifespan and healthspan. Current treatments often provide only palliative care, failing to address the underlying mechanisms of cellular senescence and inflammation that drive these conditions.
Solution
ConvEyXO is developing an exosome-based therapeutic platform designed to slow cellular aging and treat degenerative diseases. The platform leverages extracellular vesicles (EVs) derived from mesenchymal stem cells, enhancing their intrinsic anti-inflammatory and regenerative properties through the introduction of miRNA cargo. ConvEyXO's approach aims to reduce the healthspan-lifespan gap by targeting the root causes of age-related diseases, offering the potential for disease-modifying therapeutics rather than just symptom management. Their Exo-Harvest technology provides a scalable method for high-yield exosome production, while XomeXBio focuses on enhancing exosome properties.
Target Audience
ConvEyXO's primary target audience includes individuals and healthcare providers seeking treatments for age-related and degenerative diseases, as well as pharmaceutical companies looking for innovative drug delivery platforms.
Features
- Exo-Harvest: Scalable manufacturing platform utilizing a perfusion-adherent bioreactor with a 3D porous geometry scaffold to maximize exosome yield.
- Microfluidics-driven platform offering precise control over media and oxygen flow for optimal product development.
- Closed, automated system minimizing manual intervention and ensuring process robustness.
- High-throughput mini-bioreactor enabling parallel testing of 24 conditions to reduce development time and batch costs.
- AI-driven tool for geometry selection based on process data and microfluidic simulations to optimize performance.
- cGMP manufacturing capabilities with mid-scale (0.5 m2) and large clinical lot scale reactor (50 m2) under development.
- miRNA-enhanced exosome cargo for targeted anti-inflammatory and regenerative effects.